Merus Biopharmaceuticals

Merus Biopharmaceuticals

Merus is a fully-integrated biotechnology company developing cancer therapeutics that combine the benefits of monoclonal antibodies with the ability of simultaneously addressing multiple targets.  Merus has two lead programs in development, MCLA-128 for the treatment of solid tumors and MCLA-117 for the treatment of hematological malignancies.  The company is also developing a broad pipeline of preclinical programs that are available for partnering.  Merus’ technologies encompass the proprietary MeMo® transgenic mouse for common light-chain human antibodies and the CH3 heterodimerization technology for the production of full-length IgG Biclonics™. These Biclonics™ are robustly produced from a single clonal manufacturing cell line, using industry-standard systems. Merus’ Biclonics™ bind to multiple disease-associated targets, thereby eliminating tumor cells more efficiently and preventing treatment escape. In Merus´ Biclonics™-ENGAGE approach used in the MCLA-117 program, bispecific antibodies are used to induce the cytotoxic activity of T cells to kill cancer cells.

< Back to Portfolios